stockportfolio.pro
BridgeBio Pharma, Inc. (BBIO)
Healthcare · Biotechnology · NasdaqGS
BridgeBio Pharma, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $40.56M | $8.25M | $69.72M | $77.65M | $9.30M | $221.90M | $502.08M |
| Gross profit | — | — | — | — | $66.60M | $74.21M | $6.86M | $218.02M | $481.11M |
| Net income | $-43.83M | $-169.45M | $-288.58M | $-505.49M | $-586.45M | $-481.18M | $-643.20M | $-535.76M | $-724.93M |
| Net margin | — | — | -711.5% | -6127.9% | -841.2% | -619.7% | -6913.9% | -241.4% | -144.4% |
Source: BridgeBio Pharma, Inc. SEC filings (10-K).
Explore 9 years of BridgeBio Pharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BBIO in your portfolio →
BridgeBio Pharma, Inc. financial history by metric
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma, Inc. — frequently asked questions
What is BridgeBio Pharma, Inc.'s revenue?
BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.08M for fiscal year 2025, up 126.3% from the prior year, according to its SEC filings.
Is BridgeBio Pharma, Inc. profitable?
No — BBIO reported a net loss of $-724.93M in fiscal 2025.
What is BBIO's P/E ratio?
BridgeBio Pharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is BridgeBio Pharma, Inc. growing?
BBIO's revenue grew at roughly 127.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BridgeBio Pharma, Inc. have?
As of fiscal year 2025, BBIO carried roughly $1.85B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BridgeBio Pharma, Inc.'s gross margin?
BBIO's gross margin was 95.8% in fiscal 2025 — gross profit of $481.11M on revenue of $502.08M.
What is BridgeBio Pharma, Inc.'s market cap?
BridgeBio Pharma, Inc. (BBIO) has a market capitalization of about $13.25B, based on the latest data in our nightly-refreshed cache.
When does BridgeBio Pharma, Inc.'s fiscal year end?
BBIO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from BridgeBio Pharma, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.